Ionis Loses $3B in a Day: The Wainua Trial Flop That’s Testing Wall Street’s Bullish Faith

Posted on by

(SeaPRwire) –   By: Christian Pierce

Ionis Pharmaceuticals just took a sledgehammer to its market value. A 23% single-day crash erased $3 billion in investor wealth. What’s strange? Wall Street isn’t hitting the panic button. Most analysts still rate the stock a buy, even as they slash price targets. This split between market reaction and expert confidence lays bare a core anxiety in biotech: how much should investors bet on a single drug’s promise?

Wainua was supposed to be Ionis’ next big cash cow. The drug already treats hereditary transthyretin-mediated amyloid polyneuropathy. Its Phase 3 trial aimed to expand into the far larger ATTR-CM heart disease market. But the trial missed its primary endpoint. It didn’t show a statistically significant reduction in cardiovascular death or recurrent events over 140 weeks. Adding Wainua to existing stabilizer therapies gave patients no extra benefit. A subgroup on Wainua alone fared better than placebo, but those results were labeled exploratory and didn’t save the trial. Investors had pegged Wainua to generate $2 billion annually from ATTR-CM. That’s now off the table. The selloff stood out because broader biotech stocks gained that day—this was purely an Ionis-specific disaster.

Wall Street’s bullishness hinges on Ionis’ diversified pipeline. Jefferies cut its price target to $90 from $113 but kept a buy rating. It blamed unexpected strength from existing stabilizers for the trial’s failure. TD Cowen lowered its target to $94 from $108, noting Wainua’s monotherapy data matched competing drugs. Oppenheimer maintained an outperform rating, citing long-term pipeline potential. Investors are now shifting focus to TRYNGOLZA, Ionis’ newly approved drug, and other pipeline candidates. Detailed trial data will drop at the European Society of Cardiology Congress in August. Until then, the market will judge Ionis on its ability to turn TRYNGOLZA into a revenue driver. The end-game here is clear: Biotech firms can’t rely on one blockbuster to carry their valuation. Ionis will either rebuild its $3 billion loss through steady pipeline progress, or it will become another cautionary tale of overbetting on a single drug.

Author bio: Christian Pierce, chief financial columnist and markets commentator with 15 years covering biotech and pharma capital trends.